Aravive Inc. Stock News

Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago.

Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV stock today is that its Phase 3 AXLerate-OC trial did

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today

At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essenti

HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today a

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today an

Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid mark

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Although the concept of gambling on short-squeeze stocks present risks, certain market ideas drive hedge funds crazy. By this statement, I'm referring to companies that speculators believe in their he

While an extremely risky proposition, short-squeeze stocks – as meme traders demonstrated – can occasionally yield radical profitability. However, you don't want to just pick any beaten-down secur

Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +35.8% YTD. This week, the Momentum Gauges® turned negative for th

Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today a